Nicox Releases First Half 2025 Financial Results

Nicox SA, a leading international ophthalmology firm, has announced its financial outcomes for the first half of 2025. The company maintains a strategic focus on NCX 470, expecting NDA submissions in the US and China in 2026. Recent licensing payments and cost control initiatives project a solvency for the next 12 months, with plans to clear existing debts by 2026.

Financially, Nicox reported €1.5 million in revenue, a decline from the €6.1 million in the first half of 2024. Operating expenses were reduced to €6.8 million, partly due to decreased payroll following cost reduction strategies. However, a net loss of €8.9 million was recorded, up from the €4.3 million loss in 2024, influenced by forex losses.

Nicox holds €5.7 million in cash as of June 2025, with license payments pending reduction in financial debts. Strategic debt management and minimized operational costs are crucial to achieving the company's objectives.